[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-prophylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-prophylaxis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,75,98,130,159,192,219,242,268,299,331,361,390,421],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635899","perioperative-pharmacokineticpharmacodynamic-target-attainment-of-piperacillin-during-major-hepatic-and-pancreatic-surgery-100635899",false,"NCT07558681","Perioperative Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery","PROPHTAZ: Evaluation of Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study","PROPHTAZ","Inclusion Criteria:\n\n* Adults \\> or = to 18 years old\n* Scheduled for major hepatic or pancreatic surgery\n* Receiving piperacillin\u002Ftazobactam as perioperative antibiotic prophylaxis according to guidelines\n\nExclusion Criteria:\n\n* decline to participate\n* Known allergy of beta-lactam","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin\u002Ftazobactam in selected high-risk patients.\n\nHowever, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.\n\nDespite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.\n\nThe PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin\u002Ftazobactam achieves predefined pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK\u002FPD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.\n\nThis study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.",[25,26,27],"Antibiotic Prophylaxis","Pancreatic Surgey","Hepatic Surgery",[29,30,31],"PK\u002FPD target atttainment","piperacillin","surgical site infection","NOT_YET_RECRUITING","2026-04-27",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":38,"type":21},"2026-05-01",{"date":40,"type":21},"2027-05-01",{"name":42,"class":43},"Central Hospital, Nancy, France","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100614129","phase-4-antibiotic-prophylaxis-after-simple-tooth-extraction-in-immunosuppressed-patients-with-autoimmune-rheumatic-diseases-100614129","NCT07275580","Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases","Effectiveness of Short-Course Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases","PRO-EXOD","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed diagnosis of an ARD: SLE, RA, JIA, AS, PsA, IIM, systemic vasculitis, primary Sjögren's syndrome, or SSc\n* Under immunosuppressive or biologic therapy ≥3 months\n* Indication for simple extraction of tooth with chronic odontogenic focus\n* Provided informed consent\n\nExclusion Criteria:\n\n* Individuals who do not agree to participate in the study will be excluded.\n* Patients who require more technically complex extractions, such as impacted or impacted third molars.\n* Patients with local and systemic changes that require more extensive antibiotic coverage, such as cases with clinical signs of acute infections, anticoagulated patients, heart patients, patients who have undergone radiotherapy or are undergoing treatment for neoplasms.\n* Patients allergic to amoxicillin.",{"count":54,"type":21},352,"INTERVENTIONAL",[57],"PHASE4","This randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether single-dose amoxicillin prophylaxis administered prior to simple tooth extraction reduces postoperative infection rates in immunosuppressed patients with autoimmune rheumatic diseases (ARDs).\n\nAlthough antibiotic prophylaxis is not recommended for healthy individuals undergoing simple extractions, immunosuppressed ARD patients frequently receive antibiotics despite limited evidence supporting this practice.\n\nSecondary objectives include assessing infection severity, postoperative complications, and the impact of ARD diagnosis and immunosuppressive treatment on infection risk.",[60,61,62,25],"Autoimmune Rheumatic Diseases","Tooth Extraction","Infection Prevention",[60,61,62,64,65],"Amoxicillin","Antibiotic Stewardship","2026-04-14",{"date":68,"type":36},"2026-04-15",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2029-12-30",{"name":74,"class":43},"University of Sao Paulo General Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100483183","phase-4-linezolid-or-vancomycin-surgical-site-infection-prophylaxis-100483183","NCT05571722","Linezolid or Vancomycin Surgical Site Infection Prophylaxis","LOVip","Inclusion Criteria:\n\n* Patients undergoing any elective surgery for which vancomycin is recommended in the guidelines as an alternative to beta-lactams including: neurosurgery, cardiac surgery, orthopedic surgery, vascular surgery, penile and testicular surgery, gastric banding procedure in digestive surgery.\n\nThis inclusion criteria can lead to the inclusion of patients who undergo a re-intervention provided that the re-intervention is not due to a suspected or proven infection and that the patient was not included in LOVip at the time of his\u002Fher first intervention;\n\n* Age ≥ 18 years-old;\n* Known allergy to beta-lactams AND\u002FOR suspected or proven MRSA colonization. Proven MRSA colonization is defined as a positive patient sample (any type of swab or biological fluid) for MRSA within 3 months prior to surgery. MRSA colonization is suspected when the patient undergoing surgery has received antibiotic treatment within 3 months prior to surgery or is undergoing re-intervention more than 5 days after the first surgery. MRSA is defined as a strain of Staphylococcus aureus resistant to oxacillin or cefoxitin, predicting non-susceptibility to all classes of beta-lactam antimicrobials (except anti-MRSA cephalosporins) (6). In contrast, MSSA is defined as an oxacillin sensitive strain of Staphylococcus aureus;\n* Informed consent of the patient;\n* Affiliated to a social security system or equivalent.\n\nExclusion Criteria:\n\n* Surgery for suspected or proven SSI (definition of SSI provided on chapter 3.6.1 Primary endpoint as defined by (5, 7)) according to international definitions;\n* Obesity defined by a body mass index (BMI) \\> 35 kg\u002Fm2 or a body weight \\> 100 kg;\n* Chronic kidney disease defined as glomerular filtration rate (GFR) \\\u003C 60 ml\u002Fmin per 1.73m2;\n* Known allergy to linezolid or vancomycin;\n* Hematologic malignancy;\n* Declared pregnancy or breastfeeding;\n* Patient under legal protection regime for adults;\n* Patient denying consent;\n* Patient already included in LOVip for a previous surgery.",{"count":83,"type":21},1160,[57],"Anesthesia and surgical guidelines recommend the administration of a surgical antibiotic prophylaxis for patients undergoing \"clean\" surgery. The prescribed antibiotic should target the bacteria most commonly found in surgical site infections (SSIs) and the duration of administration should not exceed 24 hours to minimize the ecological risk of bacterial resistance emergence. Guidelines provide a framework for the administration of surgical antibiotic prophylaxis but their effectiveness is regularly re-evaluated by measuring the rates of SSIs and the microorganisms responsible for infectious complications after surgery.\n\nThe majority of interventions required the use of first or second generation cephalosporins as surgical antibiotic prophylaxis. For patients with allergy to beta-lactams, clindamycin and vancomycin are proposed as alternatives. In the patients with methicillin-resistant S. aureus (MRSA) colonization or if those at risk of developing MRSA-associated SSI (hospital ecology, previous antibiotic treatment), only vancomycin is recommended. Vancomycin pharmacokinetics and pharmacodynamics is complex and its tissue absorption varies according to the level of tissue inflammation. This is a difficult molecule to handle, exclusively administered via intravenous route.\n\nLinezolid is a synthetic antibiotic from the oxazolidinone class. By binding to the rRNA on the 30S and 50S ribosomal subunits, it inhibits the bacterial synthesis. It is therefore a bacteriostatic antibiotic approved for the treatment of both methicillin susceptible S. aureus (MSSA) and MRSA infections. It also covers a broad spectrum of Gram positive bacteria. Its pharmacokinetics allows rapid intravenous infusion, with rapid penetration into bone and soft tissue of the surgical site during hip surgery. A large Cochrane meta-analysis reported that linezolid was superior to vancomycin in skin infections, including MRSA infections, albeit with low quality evidence.\n\nWe therefore hypothesized that linezolid can be used instead of vancomycin for beta-lactam allergic patients and patients at risk of MRSA-associated SSI in general surgery.",[25,87],"General Surgery","RECRUITING","2026-02-03",{"date":91,"type":36},"2026-02-05",{"date":93,"type":36},"2024-11-12",{"date":95,"type":21},"2029-12-03",{"name":97,"class":43},"Assistance Publique Hopitaux De Marseille",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":55,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100615722","antibiotic-prophylaxis-versus-placebo-in-alveolar-bone-grafting-a-randomized-controlled-trial-100615722","NCT07296302","Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial","Randomized Clinical Trial Comparing Prophylactic Antibiotic Therapy and Placebo in Intraoral Alveolar Bone Grafting Procedures.","ABXGRAFT","Inclusion Criteria:\n\n* Age between 18 and 65 years.\n\nGenerally healthy individuals classified as American Society of Anesthesiologists (ASA) physical status I or II ( ASA I or ASA II).\n\nIndication for tooth extraction followed by alveolar bone grafting in a fresh socket.\n\nAbsence of active infection at the surgical site.\n\nWillingness to take amoxicillin or, in cases of β-lactam antibiotic allergy, azithromycin.\n\nNo use of antibiotics in the previous 30 days.\n\nAgreement to participate and signature of the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases or chronic use of immunosuppressive medications.\n\nPregnancy or breastfeeding.\n\nSevere liver disease.\n\nSmoking more than 10 cigarettes per day.\n\nKnown allergy to macrolides (azithromycin).\n\nPrior use of antibiotics within the last 30 days.\n\nConcomitant use of medications with known risk of QT interval prolongation.\n\nSigns of acute infection at the extraction site.",true,"65 Years",{"count":109,"type":21},150,[111],"NA","Tooth extraction sites often require alveolar bone grafting to preserve ridge dimensions and improve conditions for future implant placement. Although systemic antibiotic prophylaxis is commonly prescribed after grafting procedures, there is limited evidence supporting its necessity in healthy patients undergoing intraoral bone grafting. This randomized, double-blind, placebo-controlled clinical trial aims to compare the effects of prophylactic amoxicillin versus placebo on postoperative outcomes in alveolar bone graft procedures using Plenum® Oss HP biomaterial, a synthetic biphasic bioceramic composed of hydroxyapatite and beta-tricalcium phosphate (HA\u002Fβ-TCP; 70:30 ratio).\n\nParticipants will be randomly assigned to receive either amoxicillin 500 mg every 8 hours for 7 days or a matching placebo. Clinical parameters, postoperative complications, and patient-reported outcomes will be assessed. The study seeks to determine whether antibiotic prophylaxis provides measurable clinical benefits or whether placebo yields comparable results, contributing to more rational antibiotic use and supporting antimicrobial stewardship in oral surgery.",[114,115,25],"Alveolar Ridge Augmentation","Bone Grafting",[117,118,25,119,120],"Ridge Preservation","Alveolar Bone Graft","Synthetic Bone Graft","Biphasic Calcium Phosphate","2025-12-20",{"date":123,"type":36},"2025-12-29",{"date":125,"type":21},"2026-02",{"date":127,"type":21},"2027-08",{"name":129,"class":43},"Agnaldo Rocha de Souza Junior",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":137,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":55,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":44},"100607046","phase-4-azithromycin-and-ampicillin-for-late-pprom-100607046","NCT07183462","Azithromycin and Ampicillin for Late PPROM","ALPRO","Inclusion Criteria:\n\n* Maternal age 18-50\n* Premature rupture of membranes\n* Gestational age 34.0 and 36.4 weeks\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Multiple gestations\n* Individuals in active labor (defined as 3 cm dilatation and 80% effacement or more. or regular uterine construction of more than 4 in 10 minutes)\n* Meconium stain amniotic fluid\n* Non-reassuring fetal heart rate or status\n* Maternal or fetal indication for labor:\n\n  * Suspected Chorioamnionitis\n  * Suspected placental abruption\n  * Any maternal morbidity requiring labor\n* Cervical cerclage in place.\n* Major fetal malformation or known chromosomal abnormalities.\n* Stillbirth.\n* Sensitivity to Macrolides Antibiotics","FEMALE","50 Years",{"count":140,"type":21},311,[57],"The goal of this clinical trial is to learn whether adding azithromycin to the standard antibiotic treatment (ampicillin) improves newborn outcomes in women with preterm premature rupture of membranes (PPROM) between 34.0 and 36.6 weeks of pregnancy.\n\nThe main question it aims to answer is:\n\nDoes the combination of ampicillin and azithromycin lower the risk of serious neonatal health problems compared to ampicillin alone?\n\nResearchers will compare two antibiotic regimens:\n\nAmpicillin alone, which is the current standard care Ampicillin with azithromycin, a broader regimen that may better prevent infections and prolong pregnancy\n\nParticipants will:\n\nReceive one of the two antibiotic treatments during hospitalization. Be monitored until delivery for signs of infection and labor\n\nAll participants will stay in the hospital until delivery. The study also looks at how the antibiotic choice may affect the time between membrane rupture and delivery, maternal infections, and the need for neonatal intensive care.",[144,145,146,25,147,148],"Pregnancy Complications, Infectious","Premature Birth","Neonatal Diseases and Abnormalities","Latency Period","Prematurity","2025-12-10",{"date":151,"type":36},"2025-12-18",{"date":153,"type":36},"2025-09-10",{"date":155,"type":21},"2029-07-31",{"name":157,"class":158},"Sheba Medical Center","OTHER_GOV",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":55,"phases":170,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":44},"100601102","phase-4-antibiotics-for-kidney-transplant-recipients-100601102","NCT07106125","Antibiotics for Kidney Transplant Recipients","Trial of Antibiotic Strategies for Kidney Transplant Recipients","TASK","Inclusion Criteria:\n\n* Must be able to take capsules orally\n* Kidney transplant performed at a UCSF facility within the last 6 months\n* Most recent glomerular filtration rate (GFR) \\>30 mL\u002Fmin\u002F1.73 m2\n* Tolerated initial 6 months of post-transplant TMP-SMX (defined as no intentional periods of TMP-SMX cessation in first 6 months after transplant due to hyperkalemia, allergic reaction, or unexpected\u002Fexcessive neutropenia)\n* Considered \"high risk for UTI\" after kidney transplant, as defined by one or more of the following: (1) Congenital anomaly of kidney\u002Furinary tract as kidney failure etiology, (2) Diagnosis of neurogenic bladder and\u002For use of clean intermittent catheterization and\u002For nightly continuous urinary drainage, (3) Diabetes mellitus (diagnosed either prior to or new-onset after transplant), (4) History of recurrent UTIs as diagnosed by a provider prior to transplant, (5) Occurrence of any UTI in first 6 months after transplant, (6) Delayed graft function (defined as need for dialysis within 7 days of transplant)\n\nExclusion Criteria:\n\n* History of intolerance or allergy to trimethoprim (TMP) and\u002For sulfamethoxazole (SMX)\n* History of UTI due to a TMP-SMX-resistant organism in the first 6 months after transplant\n* Moderate or severe neutropenia (absolute neutrophil count \\\u003C1,000 cells\u002FμL) on most recent bloodwork available at the time of recruitment\n* Uncontrolled hyperkalemia (serum potassium ≥5.0 mEq\u002FL) on most recent bloodwork available at the time of recruitment\n* Provider-determined\u002Fdocumented need for either continuation or discontinuation of TMP-SMX prophylaxis that would preclude the patient's randomization\n* Current pregnancy\n* Incarcerated individuals\u002Fprisoners\n* Inability to provide informed consent or assent, and no legally authorized representative available","29 Years",{"count":169,"type":21},50,[57],"The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.\n\nThe main questions this study is asking are:\n\n* Does TMP-SMX lower the number of UTIs in the first year after transplant?\n* What side effects or problems do participants have while taking TMP-SMX?\n\nResearchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.\n\nParticipants will:\n\n* Take either TMP-SMX or a placebo pill by mouth every day for 6 months\n* Have three visits to touch base with the study team about any issues\n* Complete short monthly online surveys about any symptoms or side effects\n* Share blood and urine test results from their regular transplant clinic visits",[173,174,25,175,176],"Kidney Transplant","Urinary Tract Infection(UTI)","Remote Patient Monitoring","Feasibility Pilot Study",[178,179,180,181,182],"kidney transplant","UTI prevention","antibiotic prophylaxis","decentralized trial","remote clinical trial","2025-10-29",{"date":185,"type":36},"2025-10-31",{"date":187,"type":21},"2026-11",{"date":189,"type":21},"2029-01",{"name":191,"class":43},"University of California, San Francisco",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":199,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":55,"phases":202,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100609022","phase-3-randomized-controlled-trial-of-different-antibiotic-duration-prior-to-prostate-enucleation-surgery-100609022","NCT07209150","Randomized Controlled Trial of Different Antibiotic Duration Prior to Prostate Enucleation Surgery","Randomized Controlled Trial of 3 vs 7 Days for Perioperative Antibiotic Prophylaxis for Patients With an Indwelling Catheter Prior to Holmium Laser Enucleation of the Prostate","Inclusion Criteria:\n\n* 1\\. Candidate for HoLEP surgery 2. Must be 18 years or older. 3. The patient must be able to understand and willing to provide informed consent as described in this study protocol.\n\nExclusion Criteria:\n\n* 1\\. Under the age of 18 2. Refuse to provide informed consent 3. Anticipated need for perineal urethrostomy 4. History of multi-drug resistant organism on urine culture that is not susceptible to any oral agents","MALE",{"count":201,"type":21},250,[203],"PHASE3","To compare the risk of infectious complications (UTI, pyelonephritis, sepsis, hospital admission, ED visits) for patients with an indwelling urinary catheter (urethral or suprapubic) or CIC receiving 3 or 7 days of peri-operative antibiotic prophylaxis at time of Holmium Laser Enucleation of the Prostate",[206,25],"BPH With Urinary Obstruction",[208,209,180],"bph","urinary retention","2025-09-30",{"date":212,"type":36},"2025-10-06",{"date":214,"type":21},"2026-01-01",{"date":216,"type":21},"2028-07-15",{"name":218,"class":43},"Ohio State University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":137,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":240,"locationsCount":44},"100608395","prevalence-of-carriage-of-extended-spectrum-beta-lactamase-esbl-producing-enterobacteria-in-preterm-premature-rupture-of-membranes--a-french-multicenter-cohort-study-100608395","NCT07200999","Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study","Inclusion Criteria :\n\n* Pregnant women aged over 18 years\n* Diagnosed with premature rupture of membranes before term (between 23 weeks + 0 days and 36 weeks + 6 days of gestation)\n* Managed in one of the participating maternity hospitals\n\nExclusion Criteria :\n\n* No available microbiological sample\n* Minors or women under legal guardianship (curatorship, tutelage, or judicial protection)\n* Women who refuse the use of their clinical data for research purposes at admission or within one month after receiving the information document",{"count":201,"type":21},"This study looks at how common certain antibiotic-resistant bacteria (called extended-spectrum beta-lactamase-producing Enterobacteriaceae, or E-BLSE) are in pregnant women who experience premature breaking of their water before full term. The goal is to understand how often these bacteria are found, how long they stay, and what factors increase the risk of carrying them. This information will help doctors choose the best antibiotics to protect both the mother and baby from infections during and after pregnancy. The study follows women from the time of their membrane rupture until delivery, collecting samples to track the bacteria over time.",[228,229,230,231,25,232,233],"Premature Rupture of Membranes","Enterobacteriaceae","Beta-Lactams","Drug Resistance, Bacterial","Pregnancy","Intrauterine Infection","2025-09-23",{"date":236,"type":36},"2025-10-01",{"date":236,"type":21},{"date":239,"type":21},"2026-12-15",{"name":241,"class":43},"Centre Hospitalier de Saint-Denis",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":55,"phases":251,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":44},"100598149","cefazolin-antibiotic-prophylaxis-in-ventricular-shunt-surgery-determination-of-cerebrospinal-fluid-concentration-during-valve-implantation-100598149","NCT07067736","Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation","Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid(CSF) Concentration During Valve Implantation","CC -PIV","Inclusion Criteria:\n\nAge \\>18 years and programmed for a ventricular shunt surgery at the Hautepierre university hospital in Strasbourg.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Pregnant women\n* Infected patients\n* Known cefazolin allergy\n* Other molecule used for the antibiotic prophylaxis\n* Guardianship or conservatorship\n* Patients under curative antibiotherapy\n* Non sterile pre operative CSF\n* Refusal to participate",{"count":5,"type":21},[111],"The objective is to determine the concentration of cefazolin in the cerebrospinal fluid after a recommended antiobiotic prophylaxis by 2g of cefazolin. Our main hypothesis is that the concentration is insufficient to protect the valve from infections.\n\nThe secondary objective is to compare our results to known pharmacokinetic models of cefazolin diffusion in the literature. If differences are found we would like to search clinical features that could explain it.",[254,255,25],"Hydrocephaly","CSF Shunts",[257,258,254],"Antibiotic prophylaxis","CSF shunts","2025-08-04",{"date":261,"type":36},"2025-08-08",{"date":263,"type":21},"2025-08-01",{"date":265,"type":21},"2026-08-30",{"name":267,"class":43},"University Hospital, Strasbourg, France",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":106,"sex":199,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":277,"conditions":278,"keywords":283,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":44},"100575884","sti-prophylaxis-and-emergence-of-antimicrobial-resistance-100575884","NCT06778083","STI Prophylaxis and Emergence of Antimicrobial Resistance","SPEAR","Inclusion Criteria:\n\n* Aged ≥ 18 years.\n* Identifies as a man (cis or trans).\n* Has sex with men.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Use of an antibiotic other than doxycycline in the 3 months prior to enrolment\n* Currently being treated for an STI with doxycycline\n* Use of doxycycline within the prior 3 months for an indication other than STI treatment or STI prevention.",{"count":276,"type":21},108,"The goal of this observational study is to understand the risk of antibiotic resistance and changes in the human microbiome (bacteria that live inside and on us), if people use antibiotics to prevent sexually transmitted infections (STI prophylaxis, doxycycline post-exposure prophylaxis, or 'doxyPEP'). The study will assess how easy and acceptable it is to find antibiotic resistance and microbiome changes in the throats and guts of men-who-have-sex-with-men (MSM) who use STI prophylaxis.\n\nThe study will recruit 108 MSM who are using and not using STI prophylaxis. Participants will visit the clinic every 6 months. At each visit, they will provide a throat swab and stool sample, and complete a questionnaire. DNA of the bacteria from the samples will be analysed to identify the bacteria and look for antibiotic resistance.",[279,25,280,281,282],"Sexually Transmitted Infection (STI) Prevention","Antibiotic Resistance, Bacterial","Microbiome","Doxycycline",[284,285,282,286,287,288,281,289],"DoxyPEP","STI Prophylaxis","STI Prevention","Antimicrobial Resistance","Antibiotic Resistance","Men-who-have-sex-with-men","2025-03-26",{"date":292,"type":36},"2025-03-27",{"date":294,"type":36},"2025-02-10",{"date":296,"type":21},"2027-04-30",{"name":298,"class":43},"University College, London",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":306,"targetDuration":4,"studyType":55,"phases":307,"briefSummary":308,"conditions":309,"keywords":314,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":330},"100576953","phase-4-impact-of-probiotics-on-gut-microbiome-during-antibiotic-prophylaxis-in-elective-orthopedic-surgery-100576953","NCT06791993","Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","Impact of Probiotics Combined with Antibiotic Prophylaxis on Gut Microbiome Balance in Patients Undergoing Elective Orthopedic Surgery, Double-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Scheduled for elective low-risk orthopedic surgery (carpal tunnel release, A1 pulley release, knee arthroscopic surgery).\n\nExclusion Criteria:\n\n* History of infection or antibiotic use within the last 12 weeks.\n* Use of routine probiotics, vitamins, or herbal supplements in the last 4 weeks.\n* Known allergy to beta-lactam or cephalosporin antibiotics.\n* History of autoimmune disease, uncontrolled systemic disease, or chronic inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).\n* History of chronic intestinal diseases such as small intestine bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease.\n* Increased risk of infection due to medical comorbidities or use of immunosuppressive drugs.",{"count":20,"type":21},[57],"This study aims to evaluate whether probiotics can help maintain a healthy gut microbiome in patients receiving prophylactic antibiotics during elective orthopedic surgery. Antibiotics, while effective in preventing infections, can disrupt the balance of gut bacteria, leading to dysbiosis. The study hypothesizes that the use of probiotics during the perioperative period can prevent or reduce this disruption, supporting gut health and overall well-being. The research seeks to answer whether combining probiotics with routine antibiotic prophylaxis can preserve gut microbiome balance and improve patient outcomes.",[310,311,312,313,25],"Dysbiosis","Gut -microbiota","Microbiome Analysis","Probiotic",[315,316,317,318,25,319,320,321],"Gut Microbiome","Intestinal Dysbiosis","Surgical Site Infection","Probiotics","Human Milk Oligosaccharides (HMO)","Shotgun Metagenomic Sequencing","Short-Chain Fatty Acids (SCFAs)","2025-01-18",{"date":324,"type":36},"2025-01-24",{"date":326,"type":21},"2025-02-01",{"date":236,"type":21},{"name":329,"class":43},"Acibadem Maslak Hospital",6,{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":55,"phases":341,"briefSummary":342,"conditions":343,"keywords":348,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":360},"100570588","phase-4-clinical-trial-testing-whether-targeted-antibiotic-prophylaxis-can-reduce-infections-after-cystectomy-compared-to-empiric-prophylaxis-100570588","NCT06709196","Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.","REINFORCE","Inclusion Criteria:\n\n* Age at surgery ≥ 18 years\n* Ability to understand and sign an informed consent\n* Malignant or benign indication for undergoing cystectomy\n* Planned ileal conduit as urinary diversion\n\nExclusion Criteria:\n\n* Previous severe allergic reaction to antimicrobial treatment\n* Long-term prophylactic antibiotic treatment which is expected to be continued after the cystectomy",{"count":340,"type":21},248,[57],"The aim of this trial is to test whether postoperative antibiotics targeted towards bacteria in the urine can reduce the risk of infection after surgical removal of the bladder (cystectomy) compared to a standardised antibiotic prophylaxis.\n\nParticipants undergoing cystectomy will be randomly assigned to postoperatively receive (A) a standardised orally administered antibiotic prophylaxis currently given at Rigshospitalet, Copenhagen or (B) a conventional orally administered antibiotic prophylaxis targeting bacteria found in the urine postoperatively.\n\nThe investigators' hypothesis is that the targeted prophylactic antibiotic strategy will reduce the number of infection-related readmissions within 90 days of surgery compared to the standardised prophylaxis.",[344,345,346,25,347],"Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Ileal Conduit",[349,350],"Targeted antimicrobial prophylaxis","Infection-related readmissions","2025-01-08",{"date":353,"type":36},"2025-01-09",{"date":355,"type":36},"2025-01-07",{"date":357,"type":21},"2027-01",{"name":359,"class":43},"Rigshospitalet, Denmark",5,{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":55,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":44},"100560362","phase-3-the-role-of-antibiotic-prophylaxis-in-lowering-wound-infection-rates-post-open-repair-of-primary-elective-groin-hernias-in-high-risk-patients-100560362","NCT06576154","The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients","The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients: A Randomized Control Trial.","Inclusion Criteria:\n\n* Volunteer to participate in the study.\n* Elderly patients aged over 60 years.\n* Patients with Diabetes.\n* Or obese patients with a BMI greater than 35.\n* Or immunocompromised patients.\n* Or American Society of Anesthesiologists (ASA) physical status classification 2 or more, with a history of more than 10 years.\n\nExclusion Criteria:\n\n* Non-cooperative patients for regular follow-up.\n* Therapeutic Indication for.",{"count":369,"type":21},200,[203],"This study aims to investigate the impact of antibiotic prophylaxis on reducing wound infection rates following open repair of primary elective groin hernias in high-risk patients.",[25,373,374],"Wound Infection","Groin Hernia",[376,377,378,379,380],"Groin hernia","Postoperative complications","Wound infection","Surgical site infection","High-risk patients","2024-08-27",{"date":383,"type":36},"2024-08-28",{"date":385,"type":36},"2024-08-01",{"date":387,"type":21},"2025-09-01",{"name":389,"class":43},"University of Aleppo",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":137,"minAge":18,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":401,"conditions":402,"keywords":406,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":44},"100501740","prenatal-antibiotics-and-breast-milk--neonatal-iga-100501740","NCT05813184","Prenatal Antibiotics and Breast Milk \u002F Neonatal IgA","Effect of Prenatal Antibiotics on Breast Milk Immune Function and on the Development of Neonatal Intestinal Immune System: the Role of IgA","PAIGAN 1","Inclusion Criteria:\n\n* expression of written informed consent\n* an antibiotic treatment (any molecule) for at least 7 days consecutively after the 32 weeks of pregnancy (or the absence of exposure to any systemic antibiotic treatment during pregnancy for the control group)\n* the intention to breastfeed their neonates as long as possible during the first year of life\n\nExclusion Criteria:\n\n* absence of written informed consent\n* the intention to formula feed exclusively (or the presence of significant maternal concerns about breastfeeding)\n* a maternal antibiotic treatment shorter than 7 days\n* the presence of pre-existing maternal immune-mediated disorders (including immunodeficiencies and chronic infectious diseases)\n* a delivery at a gestational age \\\u003C 34 weeks\n* the administration of antibiotics to neonates after birth, within the first week of life.","40 Years",{"count":400,"type":21},82,"In this biological study, the investigators will evaluate the levels of breast milk IgA, neonatal fecal IgA, and the composition of breast milk and fecal microbiota throughout the first 12 months of life in neonates born to mothers treated or not treated with prenatal antibiotics for at least 7 days after the 32nd weeks of gestation",[403,25,310,404,405],"Prenatal Exposure Delayed Effects","Neonatal Infection","Breast Milk; Noxious Influence, Affecting Fetus",[407,408,409,410,411],"IgA","Prenatal antibiotics","breast milk","feces","neonatal immune system","2024-06-24",{"date":414,"type":36},"2024-06-26",{"date":416,"type":36},"2023-10-08",{"date":418,"type":21},"2025-10-30",{"name":420,"class":43},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":106,"sex":137,"minAge":18,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":55,"phases":430,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":44},"100479137","phase-4-use-of-prophylactic-antibiotics-prior-to-onabotulinumtoxina-100479137","NCT05519072","Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Female\n* Age ≥ 18\n* Patient undergoing bladder Botox treatment\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, symptomatic urinary retention or post void residual (PVR) \\> 200 mL, unwillingness or inability to initiate clean intermittent catheterization (CIC) post-treatment if required.\n* Contraindication to oral antibiotics - hypersensitivity or allergy\n* Inability to take medication by mouth",{"count":429,"type":21},140,[57],"This study aims to show that lack of antibiotic prophylaxis to those undergoing bladder Botox injections is not significantly inferior to administering prophylaxis. By proving this, the investigators aim to decrease antibiotic use in this setting to combat the growing issue of antibiotic resistance.\n\nParticipants will be randomized to antibiotic or no treatment arm. Those randomized to the treatment arm will receive oral antibiotics for 2 days pre-treatment, on the treatment day, and 2 days post-treatment. Participants will return for a follow up appointment approximately 2 weeks after treatment to assess for urinary tract infection (UTI) symptoms. They will be called again at 6 weeks for follow up.",[25],[434,435,436],"Antibiotics","Botox","OnabotulinumtoxinA","2024-03-25",{"date":439,"type":36},"2024-03-27",{"date":441,"type":36},"2022-08-16",{"date":443,"type":21},"2024-08-16",{"name":445,"class":43},"Atlantic Health System"]